Recent changes in human lifestyles have led to a global epidemic of insulin-resistant type 2 diabetes ([@B1]). Type 2 diabetes is a multisystem disorder characterized by the disruption of insulin signaling pathways critical to the integration of tissue repair and nutrient homeostasis that results in loss of protection against a range of chronic disorders of human health including arterial atherosclerosis ([@B2]). As a result, type 2 diabetes is a major cause of myocardial infarction, stroke, and peripheral vascular disease affecting millions of individuals worldwide. Insulin resistance, characterized by an initial compensatory increase in insulin production, is a progressive disorder that can differentially affect organs, tissues, cells, and intracellular signaling pathways at different stages of the disease ([@B3]).

It has recently emerged that in addition to its classical target tissues including liver, skeletal muscle, and adipose tissue, insulin resistance can occur in the endothelium where insulin has been shown to stimulate the release of the signaling radical nitric oxide (NO) ([@B4]). As a result, the endothelium, which was previously thought to be an inert lining of the blood vessel, is now established as a highly active organ that regulates a multitude of processes critical to vascular function ([@B5]).

NO, a metabolite of L-arginine to L-citrulline conversion by endothelial NO synthase (eNOS), is released by the endothelium in response to cues such as shear stress and growth factors and has a favorable effect on inflammation ([@B6]), thrombosis ([@B7]), vascular tone ([@B8]), and oxidative stress ([@B9]). A decrement in NO bioavailability may occur as a result of reduced biosynthesis and/or increased degradation by reactive oxygen species, a situation frequently described as oxidative stress ([@B10]). We have shown that insulin resistance specifically in the endothelium reduces NO bioavailability and increases the generation of potentially toxic levels of free radicals such as superoxide ([@B11],[@B12]); this supports the hypothesis that insulin resistance at the level of the endothelium contributes to accelerated vascular disease seen in individuals with type 2 diabetes, and argues for the idea that it is a legitimate therapeutic target to treat diabetes-related atherosclerosis, as suggested by Rask-Madsen et al. ([@B13]).

The compelling evidence supporting a relationship between insulin resistance and atherosclerosis has led to the development of therapies targeting insulin resistance. Peroxisome proliferator--activated receptor (PPAR)-γ is the target of the thiazolidinediones, agents that have been shown to enhance insulin sensitivity that have been used in patients with type 2 diabetes ([@B14]). However, doubts regarding the cardiovascular safety of the PPAR-γ agonist rosiglitazone have recently emerged ([@B15]). Questions remain regarding whether or not enhancing insulin sensitivity in the vascular wall of patients with type 2 diabetes is an appropriate therapeutic strategy.

Two comprehensive studies from the laboratory of Domenico Accili ([@B16],[@B17]) have begun to address this question. By deleting the three isoforms of *FoxO* specifically in the endothelium, Accili and colleagues generated a model in which the restraining effect of the *FoxO*s on endothelial insulin signaling is removed. The *FoxO* transcription factors (encoded by *FoxO1, FoxO3a*,*and FoxO4*) are downstream of Akt (a critical node in insulin-mediated NO release) and inhibit eNOS expression. Moreover, negative feedback effects of FoxOs on upstream insulin signaling elements such as Akt can also dampen insulin signaling. Endothelium-specific *FoxO*-deficient mice (*VECKO*) therefore provide a useful model to examine the effect of increased insulin action in the endothelium at different stages of type 2 diabetes.

In a model of advanced atherosclerosis and metabolic dysfunction (VECKO mice crossed onto an atherosclerosis-prone LDL receptor--deficient (*Ldlr^−/−^*) background), the Accili laboratory demonstrated that the deletion of all three *FoxO* isoforms in the endothelium has a potentially favorable effect on the development of vascular dysfunction and atherosclerosis ([@B17]). VECKO/*Ldlr*^−/−^ mice fed a Western-style diet in comparison with *Ldlr^−/−^* mice with all three isoforms of *FoxO* intact demonstrated increased arterial relaxation in response to acetylcholine, indicative of increased bioavailability of NO. Consistent with these findings, VECKO/*Ldlr*^−/−^ mice had reduced endothelial inflammation, reduced oxidative stress, and less atherosclerosis. By contrast, in this model of metabolic and vascular dysfunction, no beneficial effect on metabolic parameters or glucose homeostasis was shown. These data present a relatively straightforward paradigm whereby increasing insulin sensitivity in the endothelium has a favorable effect on NO bioavailability and atherosclerosis.

In the second part of the story, which is highlighted in this issue of *Diabetes,* a more complex picture emerges. Tsuchiya and Accili ([@B16]) examined the effect of the deletion of the *FoxO*s in mouse endothelium against a C57BL/6 background and standard chow diet. Intriguingly, standard chow--fed VECKO mice were glucose intolerant and had reduced insulin sensitivity; the defect in insulin action was identified as being in the liver. As expected, increasing insulin sensitivity in liver endothelial cells by deleting the *FoxO*s increased eNOS-derived NO. Surprisingly, NO reduced hepatic insulin sensitivity by tyrosine nitration of the insulin receptor in hepatocytes. Further experiments confirmed the source of the NO as eNOS rather than the inducible isoform iNOS, which has been shown to have a pathophysiological role in obesity-related insulin resistance ([@B18]). Complementary studies of hyperinsulinemia produced similar results, and inhibiting eNOS in a model of early insulin resistance had favorable effects on glucose homeostasis. It should be noted that the effect of *FoxO* deletion on endothelial cell function in the aorta or other arteries was not examined; it would be interesting to know whether or not---despite insulin resistance and glucose intolerance---*FoxO* deletion in the endothelium has a favorable effect on endothelial cell function in atherosclerosis-prone vessels ([Fig. 1](#F1){ref-type="fig"}).
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So where does the phenotype of the endothelium-specific *FoxO*-deficient mouse leave us? The new data support insulin sensitization in the vascular endothelium as a useful strategy in advanced vascular disease. The data from mice without the severe insult of hypercholesterolemia are more challenging to reconcile with our current way of thinking about NO and type 2 diabetes. With the important caveat that the effect of different mechanisms of enhancing insulin sensitivity in the endothelium other than the deletion of FoxOs need to be examined, Tsuchiya and Accili ([@B16]) show that, in the case of NO and hepatic glucose homeostasis, it is possible to get too much of a good thing. Their results raise the exciting possibility that the hyperinsulinemia of early insulin resistance is a legitimate therapeutic target.

See accompanying original article, p. 1478.
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